Methods to assess adverse health-related outcomes in cancer survivors

Cancer Epidemiology Biomarkers and Prevention

Volumn 20, Issue 10, 2011, Pages 2022-2034

  Oeffinger, Kevin C ^a   Van Leeuwen, Flora E ^b   Hodgson, David C ^c  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER SURVIVAL; CANCER SURVIVOR; CONFOUNDING VARIABLE; HUMAN; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT;

BIOMEDICAL RESEARCH; CASE-CONTROL STUDIES; COHORT STUDIES; HUMANS; NEOPLASMS; OUTCOME ASSESSMENT (HEALTH CARE); PROGNOSIS; RESEARCH DESIGN; SURVIVAL RATE; SURVIVORS;

EID: 80053489349     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-11-0674     Document Type: Review

References (143)

1. Hodgson DC, Van Leeuwen FE. Second malignancy risk after treatment of Hodgkin lymphoma. In:Engert A, Horning SJ, editors. Hodgkin lymphoma. Berlin Heidelberg; Springer-Verlag: 2011. p. 305-31.
2. Kaldor JM, Day NE, Shiboski S. Epidemiological studies of anticancer drug carcinogenicity. IARC Sci Publ 1986:189-201.
3. Travis LB, Bhatia S, Allan JM, Oeffinger KC, Ng A. Second cancers. In: DeVita VT Jr. HSRS editor. Cancer: principles and practice of oncology. Philadelphia: Lippincott; 2011. p. 2393-410.
4. Travis LB, Hodgson DC, Allan JM, Van Leeuwen FE. Second cancers. In:DeVita VT Jr. HSRS editor. Cancer: principles and practice of oncology. Philadelphia: Lippincott; 2008. p. 2718-42.
5. Vandenbroucke JP. When are observational studies as credible as randomised trials? Lancet 2004;363:1728-31. (Pubitemid 38670333)
6. Robison LL, Mertens AC, Boice JD, Breslow NE, Donaldson SS, Green DM, et al. Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. Med Pediatr Oncol 2002;38:229-39. (Pubitemid 34258414)
7. Bhatia S, Yasui Y, Robison LL, Birch JM, Bogue MK, Diller L, et al. High risk of subsequent neoplasms continues with extended followup of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol 2003;21:4386-94. (Pubitemid 46621816)
8. Curtis RERies LAG. Methods. In:Curtis RE, Freedman DM, Ron E, et al., editors. New Malignancies Among Cancer Survivors: SEER Cancer Registries 1973-2000. Bethesda, MD: NIH Publ. No. 05-5302; 2006. p. 9-14.
9. Reulen RC, Frobisher C, Winter DL, Kelly J, Lancashire ER, Stiller CA, et al. Long-term risks of subsequent primary neoplasms among survivors of childhood cancer. JAMA 2011;305:2311-9.
10. Reulen RC, Winter DL, Frobisher C, Lancashire ER, Stiller CA, Jenney ME, et al. Long-term cause-specific mortality among survivors of childhood cancer. JAMA 2010;304:172-9.
11. Gillessen S, Templeton A, Marra G, Kuo YF, Valtorta E, Shahinian VB. Risk of colorectal cancer in men on long-term androgen deprivation therapy for prostate cancer. J Natl Cancer Inst 2010;102:1760-70.
12. Ganz PA, Land SR, Antonio C, Zheng P, Yothers G, Petersen L, et al. Cancer survivorship research: the challenge of recruiting adult long term cancer survivors from a cooperative clinical trials group. J Cancer Surviv 2009;3:137-47.
13. Bhatia S, Krailo MD, Chen Z, Burden L, Askin FB, Dickman PS, et al. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group. Blood 2007;109:46-51. (Pubitemid 46053041)
14. Travis LB, Beard C, Allan JM, Dahl AA, Feldman DR, Oldenburg J, et al. Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst 2010;102:1114-30.
15. Coleman CN, Williams CJ, Flint A, Glatstein EJ, Rosenberg SA, Kaplan HS. Hematologic neoplasia in patients treated for Hodgkin's disease. N Engl J Med 1977;297:1249-52. (Pubitemid 8241171)
16. Hancock SL, Tucker MA, Hoppe RT. Breast cancer after treatment of Hodgkin's disease. J Natl Cancer Inst 1993;85:25-31. (Pubitemid 23023219)
17. Ng AK, Bernardo MV, Weller E, Backstrand K, Silver B, Marcus KC, et al. Second malignancy after Hodgkin disease treated with radiation therapy with or without chemotherapy: long-term risks and risk factors. Blood 2002;100:1989-96. (Pubitemid 35001228)
18. De Bruin ML, Sparidans J, van't Veer MB, Noordijk EM, Louwman MW, Zijlstra JM, et al. Breast cancer risk in female survivors of Hodgkin's lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 2009;27:4239-46.
19. Geenen MM, Cardous-Ubbink MC, Kremer LC, Van den Bos C, Van der Pal HJ, Heinen RC, et al. Medical assessment of adverse health outcomes in long-term survivors of childhood cancer. JAMA 2007;297:2705-15. (Pubitemid 47001096)
20. Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 2009;339:b4606.
21. Oeffinger KC, Mertens AC, Sklar CA, Kawashima T, Hudson MM, Meadows AT, et al. Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 2006;355:1572-82. (Pubitemid 44547808)
22. Kaldor JM, Day NE, Clarke EA, Van Leeuwen FE, Henry-Amar M, Fiorentino MV, et al. Leukemia following Hodgkin's disease. N Engl J Med 1990;322:7-13. (Pubitemid 20023826)
23. Kaldor JM, Day NE, Band P, Choi NW, Clarke EA, Coleman MP, et al. Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registries. Int J Cancer 1987;39:571-85. (Pubitemid 17084728)
24. Demark-Wahnefried W, Bowen DJ, Jabson JM, Paskett ED. Scientific bias arising from sampling, selective recruitment, and attrition: the case for improved reporting. Cancer Epidemiol Biomarkers Prev 2011;20:415-8.
25. Boice JD Jr, Blettner M, Kleinerman RA, Stovall M, Moloney WC, Engholm G, et al. Radiation dose and leukemia risk in patients treated for cancer of the cervix. J Natl Cancer Inst 1987;79:1295-311. (Pubitemid 18036735)
26. Boice JD Jr, Harvey EB, Blettner M, Stovall M, Flannery JT. Cancer in the contralateral breast after radiotherapy for breast cancer. N Engl J Med 1992;326:781-5.
27. Curtis RE, Boice JD Jr, Stovall M, Bernstein L, Greenberg RS, Flannery JT, et al. Risk of leukemia after chemotherapy and radiation treatment for breast cancer. N Engl J Med 1992;326:1745-51.
28. Inskip PD, Robison LL, Stovall M, Smith SA, Hammond S, Mertens AC, et al. Radiation dose and breast cancer risk in the childhood cancer survivor study. J Clin Oncol 2009;27:3901-7.
29. Sigurdson AJ, Ronckers CM, Mertens AC, Stovall M, Smith SA, Liu Y, et al. Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study. Lancet 2005;365:2014-23. (Pubitemid 40805009)
30. Travis LB, Curtis RE, Glimelius B, Holowaty EJ, Van Leeuwen FE, Lynch CF, et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 1995;87:524-30.
31. Travis LB, Gospodarowicz M, Curtis RE, Clarke EA, Andersson M, Glimelius B, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002;94:182-92. (Pubitemid 34162752)
32. Travis LB, Hill DA, Dores GM, Gospodarowicz M, Van Leeuwen FE, Holowaty E, et al. Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. JAMA 2003;290:465-75. (Pubitemid 37430500)
33. Tucker MA, D'Angio GJ, Boice JD Jr, Strong LC, Li FP, Stovall M, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 1987;317:588-93. (Pubitemid 17126781)
34. Tucker MA,Meadows AT, Boice JD Jr, Stovall M, Oberlin O, Stone BJ, et al. Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst 1987;78:459-64. (Pubitemid 17036759)
35. Van Leeuwen FE, Klokman WJ, Stovall M, Dahler EC, van't Veer MB, Noordijk EM, et al. Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 2003;95:971-80. (Pubitemid 36896714)
36. Neglia JP, Robison LL, Stovall M, Liu Y, Packer RJ,Hammond S, et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2006;98:1528-37. (Pubitemid 44680904)
37. Van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrere CH, Otter R, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:448-52. (Pubitemid 24059587)
38. Bergman L, Beelen ML, Gallee MP, Hollema H, Benraadt J, Van Leeuwen FE. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen. Lancet 2000;356:881-7.
39. Travis LB. The epidemiology of second primary cancers. Cancer Epidemiol Biomarkers Prev 2006;15:2020-6. (Pubitemid 44883051)
40. Breslow NE, Day NE. Statistical mathods in cancer research. Volume 1 - The analysis of case-control studies, chapter 3. IARC Scietific Publishers No 32; 1980.
41. Sasieni P. Endometrial cancer during tamoxifen treatment. Lancet 1994;343:978.
42. Van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrere CH, Otter R, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:448-52. (Pubitemid 24059587)
43. Van den Belt-Dusebout AW, Aleman BM, Besseling G, De Bruin ML, Hauptmann M, van't Veer MB, et al. Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. Int J Radiat Oncol Biol Phys 2009;75:1420-9.
44. O'Brien MM, Donaldson SS, Balise RR, Whittemore AS, Link MP. Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy. J Clin Oncol 2010;28:1232-9.
45. Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. JAMA 2003;290: 2831-7. (Pubitemid 37509491)
46. Ness KK, Leisenring W, Goodman P, Kawashima T, Mertens AC, Oeffinger KC, et al. Assessment of selection bias in clinic-based populations of childhood cancer survivors: a report from the childhood cancer survivor study. Pediatr Blood Cancer 2009;52:379-86.
47. Cuzick J, Stewart H, Rutqvist L,Houghton J, Edwards R,Redmond C, et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 1994;12: 447-53. (Pubitemid 24079884)
48. Hooning MJ, Aleman BM, Van Rosmalen AJ, Kuenen MA, Klijn JG, Van Leeuwen FE. Cause-specific mortality in long-term survivors of breast cancer: A 25-year follow-up study. Int J Radiat Oncol Biol Phys 2006;64:1081-91.
49. Hooning MJ, Botma A, Aleman BM, Baaijens MH, Bartelink H, Klijn JG, et al. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Inst 2007;99:365-75. (Pubitemid 47073480)
50. Robison LL, Armstrong GT, Boice JD, Chow EJ, Davies SM, Donaldson SS, et al. The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research. J Clin Oncol 2009;27:2308-18.
51. Green DM, Kawashima T, Stovall M, Leisenring W, Sklar CA, Mertens AC, et al. Fertility of female survivors of childhood cancer: a report from the childhood cancer survivor study. J Clin Oncol 2009; 27:2677-85.
52. Sklar CA, Mertens AC, Mitby P, Whitton J, Stovall M, Kasper C, et al. Premature menopause in survivors of childhood cancer: a report from the childhood cancer survivor study. J Natl Cancer Inst 2006;98:890-6. (Pubitemid 44018918)
53. Smith Sehdev AE, Hutchins GM. Problems with proper completion and accuracy of the cause-of-death statement. Arch Intern Med 2001;161:277-84. (Pubitemid 32102397)
54. Begg CB, Schrag D. Attribution of deaths following cancer treatment. J Natl Cancer Inst 2002;94:1044-5. (Pubitemid 34830718)
55. Howlader N, Ries LA, Mariotto AB, Reichman ME, Ruhl J, Cronin KA. Improved estimates of cancer-specific survival rates from population- based data. J Natl Cancer Inst 2010;102:1584-98.
56. Moriyama IM, Loy RM, Robb-Smith AHT, Rosenberg HM, Hoyert DLNational Center for Health Statistics (U.S.). History of the statistical classification of diseases and causes of death. Hyattsville, Md.: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, National Center for Health Statistics; 2011.
57. Seshasai SR, Kaptoge S, Thompson A, Di Angelantonio E, Gao P, Sarwar N, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364:829-41.
58. Flegal KM, Graubard BI, Williamson DF, Gail MH. Cause-specific excess deaths associated with underweight, overweight, and obesity. JAMA 2007;298:2028-37. (Pubitemid 350074800)
59. Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD, et al. Long-term mortality after gastric bypass surgery. N Engl J Med 2007;357:753-61. (Pubitemid 47295642)
60. Kaptoge S, Di Angelantonio E, Lowe G, Pepys MB, Thompson SG, Collins R, et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010;375:132-40.
61. Erqou S, Kaptoge S, Perry PL, Di Angelantonio E, Thompson A, White IR, et al. Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009;302:412-23.
62. Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, et al., editors. New Malignancies among cancer survivors: SEER cancer registries, 1973-2000. Bethesda, MD; National Cancer Institute 2006.
63. Morton LM, Curtis RE, Linet MS, Bluhm EC, Tucker MA, Caporaso N, et al. Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype. J Clin Oncol 2010;28:4935-44.
64. Dores GM, Anderson WF, Beane Freeman LE, Fraumeni JF Jr, Curtis RE. Risk of breast cancer according to clinicopathologic features among long-term survivors of Hodgkin's lymphoma treated with radiotherapy. Br J Cancer 2010;103:1081-4.
65. Bhaskarla A, Tang PC, Mashtare T, Nwogu CE, Demmy TL, Adjei AA, et al. Analysis of second primary lung cancers in the SEER database. J Surg Res 2010;162:1-6.
66. Singh AK, Mashtare TL, McCloskey SA, Seixas-Mikelus SA, Kim HL, May KS. Increasing age and treatment modality are predictors for subsequent diagnosis of bladder cancer following prostate cancer diagnosis. Int J Radiat Oncol Biol Phys 2010;78:1086-94.
67. Bradford PT, Freedman DM,Goldstein AM, Tucker MA. Increased risk of second primary cancers after a diagnosis of melanoma. Arch Dermatol 2010;146:265-72.
68. Spanogle JP, Clarke CA, Aroner S, Swetter SM. Risk of second primary malignancies following cutaneous melanoma diagnosis: a population-based study. J Am Acad Dermatol 2010;62:757-67.
69. Wright JD, St Clair CM, Deutsch I, Burke WM, Gorrochurn P, Sun X, et al. Pelvic radiotherapy and the risk of secondary leukemia and multiple myeloma. Cancer 2010;116:2486-92.
70. Berrington de Gonzalez A, Curtis RE, Gilbert E, Berg CD, Smith SA, Stovall M, et al. Second solid cancers after radiotherapy for breast cancer in SEER cancer registries. Br J Cancer 2010;102:220-6.
71. Brown AP, Neeley ES, Werner T, Soisson AP, Burt RW, Gaffney DK. A population-based study of subsequent primary malignancies after endometrial cancer: genetic, environmental, and treatment-related associations. Int J Radiat Oncol Biol Phys 2010;78:127-35.
72. Abdel-Wahab M, Reis IM, Wu J, Duncan R. Second primary cancer risk of radiation therapy after radical prostatectomy for prostate cancer: an analysis of SEER data. Urology 2009;74:866-71.
73. Mery CM, George S, Bertagnolli MM, Raut CP. Secondary sarcomas after radiotherapy for breast cancer: sustained risk and poor survival. Cancer 2009;115:4055-63.
74. Martin MG, Welch JS, Luo J, Ellis MJ, Graubert TA, Walter MJ. Therapy related acute myeloid leukemia in breast cancer survivors, a population-based study. Breast Cancer Res Treat 2009;118:593-8.
75. Kumar S, Shah JP, Bryant CS, Awonuga AO, Imudia AN, Ruterbusch JJ, et al. Second neoplasms in survivors of endometrial cancer: impact of radiation therapy. Gynecol Oncol 2009;113:233-9.
76. Boukheris H, Ron E, Dores GM, Stovall M, Smith SA, Curtis RE. Risk of radiation-related salivary gland carcinomas among survivors of Hodgkin lymphoma: a population-based analysis. Cancer 2008; 113:3153-9.
77. Rusthoven KE, Flaig TW, Raben D, Kavanagh BD. High incidence of lung cancer after non-muscle-invasive transitional cell carcinoma of the bladder: implications for screening trials. Clin Lung Cancer 2008;9:106-11. (Pubitemid 351631922)
78. Abdel-Wahab M, Reis IM, Hamilton K. Second primary cancer after radiotherapy for prostate cancer-a seer analysis of brachytherapy versus external beam radiotherapy. Int J Radiat Oncol Biol Phys 2008;72:58-68.
79. Brown AP, Chen J, Hitchcock YJ, Szabo A, Shrieve DC, Tward JD. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. J Clin Endocrinol Metab 2008;93:504-15. (Pubitemid 351240823)
80. Chaturvedi AK, Engels EA, Gilbert ES, Chen BE, Storm H, Lynch CF, et al. Second cancers among 104,760 survivors of cervical cancer: evaluation of long-term risk. J Natl Cancer Inst 2007;99:1634-43.
81. Kendal WS, Nicholas G. A population-based analysis of second primary cancers after irradiation for rectal cancer. Am J Clin Oncol 2007;30:333-9. (Pubitemid 47356675)
82. Travis LB, Fossa SD, Schonfeld SJ, McMaster ML, Lynch CF, Storm H, et al. Second cancers among 40,576 testicular cancer patients: focus on long-term survivors. J Natl Cancer Inst 2005;97:1354-65. (Pubitemid 41487803)
83. Travis LB, Andersson M, Gospodarowicz M, Van Leeuwen FE, Bergfeldt K, Lynch CF, et al. Treatment-associated leukemia following testicular cancer. J Natl Cancer Inst 2000;92:1165-71.
84. Friedman DL, Whitton J, Leisenring W, Mertens AC, Hammond S, Stovall M, et al. Subsequent neoplasms in 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2010;102:1083-95.
85. Van Leeuwen FE, Klokman WJ, Veer MB, Hagenbeek A, Krol AD, Vetter UA, et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. J Clin Oncol 2000;18:487-97. (Pubitemid 30078530)
86. Perkins JL, Liu Y, Mitby PA, Neglia JP, Hammond S, Stovall M, et al. Nonmelanoma skin cancer in survivors of childhood and adolescent cancer: a report from the childhood cancer survivor study. J Clin Oncol 2005;23:3733-41.
87. Cancer Therapy Evaluation Program. Common terminology criteria for adverse events, version 3.0. DCTD, NCI, NIH, DHHS. March 31, 2003. Available from: http://ctep.cancer.gov. [Publish Date: August 9, 2006].
88. Robison LL. Treatment-associated subsequent neoplasms among long-term survivors of childhood cancer: the experience of the Childhood Cancer Survivor Study. Pediatr Radiol 2009;39 Suppl 1: S32-7.
89. Oeffinger KC, Robison LL. Childhood cancer survivors, late effects, and a new model for understanding survivorship. JAMA 2007;297: 2762-4. (Pubitemid 47001104)
90. Armstrong GT, Stovall M, Robison LL. Long-term effects of radiation exposure among adult survivors of childhood cancer: results from the childhood cancer survivor study. Radiat Res 2010;174:840-50.
91. Castellino SM, Geiger AM, Mertens AC, Leisenring WM, Tooze JA, Goodman P, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood 2011;117:1806-16.
92. Nagarajan R, Kamruzzaman A, Ness KK, Marchese VG, Sklar C, Mertens A, et al. Twenty years of follow-up of survivors of childhood osteosarcoma: A report from the childhood cancer survivor study. Cancer 2011;117:625-34.
93. Armstrong GT, Stovall M, Robison LL. Long-term effects of radiation exposure among adult survivors of childhood cancer: results from the childhood cancer survivor study. Radiat Res 2010;174:840-50.
94. Ginsberg JP, Goodman P, Leisenring W, Ness KK, Meyers PA, Wolden SL, et al. Long-term survivors of childhood Ewing sarcoma: report from the childhood cancer survivor study. J Natl Cancer Inst 2010;102:1272-83.
95. Goldsby RE, Liu Q, Nathan PC, Bowers DC, Yeaton-Massey A, Raber SH, et al. Late-occurring neurologic sequelae in adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2010;28:324-31.
96. Laverdiere C, Liu Q, Yasui Y, Nathan PC, Gurney JG, Stovall M, et al. Long-term outcomes in survivors of neuroblastoma: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst 2009;101:1131-40.
97. Armstrong GT, Liu Q, Yasui Y, Huang S, Ness KK, Leisenring W, et al. Long-term outcomes among adult survivors of childhood central nervous system malignancies in the Childhood Cancer Survivor Study. J Natl Cancer Inst 2009;101:946-58.
98. Diller L, Chow EJ, Gurney JG, Hudson MM, Kadin-Lottick NS, Kawashima TI, et al. Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings. J Clin Oncol 2009;27:2339-55.
99. Mody R, Li S, Dover DC, Sallan S, Leisenring W, Oeffinger KC, et al. Twenty-five-year follow-up among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Blood 2008;111:5515-23.
100. Mulrooney DA, Dover DC, Li S, Yasui Y, Ness KK, Mertens AC, et al. Twenty years of follow-up among survivors of childhood and young adult acute myeloid leukemia: a report from the Childhood Cancer Survivor Study. Cancer 2008;112:2071-9. (Pubitemid 351574084)
101. Van der Pal HJ, Van Dalen EC, Hauptmann M, Kok WE, Caron HN, Van den Bos C, et al. Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. Arch Intern Med 2010;170: 1247-55.
102. Geenen MM, Bakker PJ, Kremer LC, Kastelein JJ, Van Leeuwen FE. Increased prevalence of risk factors for cardiovascular disease in long-term survivors of acute lymphoblastic leukemia and Wilms tumor treated with radiotherapy. Pediatr Blood Cancer 2010; 55:690-7.
103. Louie A, Robison LL, Bogue MK, Forman SJ, Bhatia S. Validation of self-reported complications by bone marrow transplantation survivors. Bone Marrow Transplantation 2000;25:1191-96. (Pubitemid 30345255)
104. McGale P, Darby SC, Hall P, Adolfsson J, Bengtsson N, Bennet AM, et al. Incidence of heart disease in 35,000 women treated with radiotherapy for breast cancer in Denmark and Sweden. Radiother Oncol 2011; [Epub ahead of print].
105. Leisenring WM, Mertens AC, Armstrong GT, Stovall MA, Neglia JP, Lanctot JQ, et al. Pediatric cancer survivorship research: experience of the Childhood Cancer Survivor Study. J Clin Oncol 2009;27: 2319-27.
106. Garmey EG, Liu Q, Sklar CA, Meacham LR, Mertens AC, Stovall MA, et al. Longitudinal changes in obesity and body mass index among adult survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 2008; 26:4639-45.
107. Kadan-Lottick NS, Robison LL, Gurney JG, Neglia JP, Yasui Y, Hayashi R, et al. Childhood cancer survivors' knowledge about their past diagnosis and treatment: Childhood Cancer Survivor Study. JAMA 2002;287:1832-9. (Pubitemid 34303628)
108. Travis LB, Hill D, Dores GM, Gospodarowicz M, Van Leeuwen FE, Holowaty E, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 2005; 97:1428-37. (Pubitemid 41520078)
109. Ng A, Nguyen TN, Moseley JL, Hodgson DC, Sharpe MB, Brock KK. Reconstruction of 3D lung models from 2D planning data sets for Hodgkin's lymphoma patients using combined deformable image registration and navigator channels. Med Phys 2010;37:1017-28.
110. Taylor CW, Nisbet A, McGale P, Goldman U, Darby SC, Hall P, et al. Cardiac doses from Swedish breast cancer radiotherapy since the 1950s. Radiother Oncol 2009;90:127-35.
111. Nathan PC, Ford JS, Henderson TO, Hudson MM, Emmons KM, Casillas JN, et al. Health behaviors, medical care, and interventions to promote healthy living in the Childhood Cancer Survivor Study cohort. J Clin Oncol 2009;27:2363-73.
112. Bhatia S, Robison LL. Cancer survivorship research: opportunities and future needs for expanding the research base. Cancer Epidemiol Biomarkers Prev 2008;17:1551-7.
113. Oeffinger KC, Bhatia S. Second primary cancers in survivors of childhood cancer. Lancet 2009;374:1484-5.
114. Rogers NL, Cole SA, Lan HC, Crossa A, Demerath EW. New saliva DNA collection method compared to buccal cell collection techniques for epidemiological studies. Am J Hum Biol 2007;19:319-26. (Pubitemid 46839443)
115. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373-83. (Pubitemid 17055592)
116. De Groot V, Beckerman H, Lankhorst GJ, Bouter LM. Howto measure comorbidity. a critical review of available methods. J Clin Epidemiol 2003;56:221-9. (Pubitemid 36513483)
117. Piccirillo JF. Importance of comorbidity in head and neck cancer. Laryngoscope 2000;110:593-602. (Pubitemid 30198711)
118. Piccirillo JF, Lacy PD, Basu A, Spitznagel EL. Development of a new head and neck cancer-specific comorbidity index. Arch Otolaryngol Head Neck Surg 2002;128:1172-9. (Pubitemid 35168108)
119. Piccirillo JF, Tierney RM, Costas I, Grove L, Spitznagel EL Jr. Prognostic importance of comorbidity in a hospital-based cancer registry. JAMA 2004;291:2441-7. (Pubitemid 38669187)
120. Aleman BM, Van den Belt-Dusebout AW, De Bruin ML, Van 't Veer MB, Baaijens MH, De Boer JP, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007;109:1878-86. (Pubitemid 46348183)
121. Armstrong GT, Liu Q, Yasui Y, Neglia JP, Leisenring W, Robison LL, et al. Late mortality among 5-year survivors of childhood cancer: a summary from the Childhood Cancer Survivor Study. J Clin Oncol 2009;27:2328-38.
122. Mertens AC, Liu Q, Neglia JP, Wasilewski K, Leisenring W, Armstrong GT, et al. Cause-specific late mortality among 5-year survivors of childhood cancer: the Childhood Cancer Survivor Study. J Natl Cancer Inst 2008;100:1368-79.
123. Aleman BM, Van den Belt-Dusebout AW, Klokman WJ, Van't Veer MB, Bartelink H, Van Leeuwen FE. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003;21:3431-9. (Pubitemid 46603515)
124. Ng AK, Bernardo MP, Weller E, Backstrand KH, Silver B, Marcus KC, et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. J Clin Oncol 2002;20:2101-8. (Pubitemid 34408801)
125. Pintilie M. Dealing with competing risks: testing covariates and calculating sample size. Stat Med 2002;21:3317-24. (Pubitemid 35314652)
126. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18:695-706. (Pubitemid 29126745)
127. Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B, et al. Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 2002;20:3484-94.
128. Hudson MM, Mertens AC, Yasui Y, Hobbie W, Chen H, Gurney JG, et al. Health status of adult long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. JAMA 2003; 290:1583-92. (Pubitemid 37430383)
129. Zebrack BJ, Gurney JG, Oeffinger K, Whitton J, Packer RJ, Mertens A, et al. Psychological outcomes in long-term survivors of childhood brain cancer: a report from the childhood cancer survivor study. J Clin Oncol 2004;22:999-1006. (Pubitemid 41095031)
130. Belot A, Abrahamowicz M, Remontet L, Giorgi R. Flexible modeling of competing risks in survival analysis. Stat Med 2010;29:2453-68.
131. Korn EL, Graubard BI, Midthune D. Time-to-event analysis of longitudinal follow-up of a survey: choice of the time-scale. Am J Epidemiol 1997;145:72-80. (Pubitemid 27009060)
132. Van Walraven C, Davis D, Forster AJ, Wells GA. Time-dependent bias was common in survival analyses published in leading clinical journals. J Clin Epidemiol 2004;57:672-82. (Pubitemid 39195217)
133. Austin PC. A critical appraisal of propensity-score matching in the medical literature between 1996 and 2003. Stat Med 2008;27: 2037-49. (Pubitemid 351772300)
134. Chamie K, Kurzrock EA, Evans CP, Litwin MS, Koppie TM, Wootton-Gorges SL, et al. Secondary malignancies among nonseminomatous germ cell tumor cancer survivors. Cancer 2011 [Epub ahead of print].
135. Hodgson DC, Koh ES, Tran TH, Heydarian M, Tsang R, Pintilie M, et al. Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma. Cancer 2007;110: 2576-86. (Pubitemid 350174945)
136. Sachs RK, Shuryak I, Brenner D, Fakir H, Hlatky L, Hahnfeldt P. Second cancers after fractionated radiotherapy: stochastic population dynamics effects. J Theor Biol 2007;249:518-31. (Pubitemid 350046627)
137. Schneider U, Lomax A, Pemler P, Besserer J, Ross D, Lombriser N, et al. The impact of IMRT and proton radiotherapy on secondary cancer incidence. Strahlenther Onkol 2006;182:647-52. (Pubitemid 44657651)
138. Schneider U, Walsh L. Cancer risk estimates from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy. Radiat Environ Biophys 2008;47:253-63.
139. Zwahlen DR, Martin JM, Millar JL, Schneider U. Effect of radiotherapy volume and dose on secondary cancer risk in stage I testicular seminoma. Int J Radiat Oncol Biol Phys 2008;70:853-8.
140. Kry SF, Followill D, White RA, Stovall M, Kuban DA, Salehpour M. Uncertainty of calculated risk estimates for secondary malignancies after radiotherapy. Int J Radiat Oncol Biol Phys 2007;68: 1265-71. (Pubitemid 47048597)
141. Von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 2007;4:e296.
142. Vandenbroucke JP, Von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med 2007;4:e297.
143. Cancer Therapy Evaluation Program. Common Terminology Criteria for Adverse Events, Version 4.0. DCTD, NCI, NIH, DHHS. (http://ctep.cancer.gov).